期刊
CURRENT DIABETES REPORTS
卷 13, 期 5, 页码 608-615出版社
CURRENT MEDICINE GROUP
DOI: 10.1007/s11892-013-0405-9
关键词
Autoantigen; Autoantibody; Zinc transporter 8; Type 1 diabetes
资金
- DERC [R01 DK052068, JDRF 4-2007-1056, P30 DK057516]
- Childhood Diabetes Foundation (CDF) for an Acorn award
Autoantibodies are currently the most robust biomarkers of type 1 diabetes and are frequently used to establish entry criteria for the participation of genetically at-risk individuals in secondary prevention/intervention clinical trials. Since their original description almost 40 years ago, considerable efforts have been devoted toward identifying the precise molecular targets that are recognized. Such information can have significant benefit for developing improved metrics for identifying/stratifying of at-risk subjects, developing potential therapeutic targets, and advancing understanding of the pathophysiology of the disease. Currently, four major molecular targets ([pro]insulin, GAD65, IA-2, and ZnT8) have been confirmed, with approximately 94% of all subjects with a clinical diagnosis of type 1 diabetes expressing autoantibodies to at least one of these molecules at clinical onset. In this review, we summarize some of the salient properties of these targets that might contribute to their autoantigenicity and methods that have been used in attempts to identify new components of the humoral autoresponse.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据